Inherited Neuropathies Consortium (INC)
Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, affecting approximately 1 in 2,500 people in the United States. CMT, also known as hereditary motor and sensory neuropathy or peroneal muscular atrophy, comprises a group of disorders that affect peripheral nerves. The Inherited Neuropathy Consortium (INC) is a network of researchers working to find the best treatments for CMT. Over the past few years, the INC has carried out studies, identified multiple genetic causes of CMT, begun testing possible markers for CMT, enrolled thousands of patients in its studies, trained young scientists in CMT research, and created a website that provides information about CMT to patients, families, and researchers. INC’s future goals include conducting further natural history studies to enable clinical trials, continuing the search for biological features (biomarkers) of disease, continuing to identify novel genetic causes and modifiers of CMT, and continuing to provide information to patients, their families, doctors and researchers.
The Inherited Neuropathy Consortium (INC) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). INC is funded under grant number U54NS065712 as a collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS). All RDCRN consortia are supported by the network’s Data Management and Coordinating Center (DMCC) (U2CTR002818). Funding support for the DMCC is provided by NCATS and NINDS.